Connect with us

Bloomberg Technology

FDA Approves First Crispr Treatment for Sickle Cell Disease

A gene-editing therapy for sickle cell disease was approved by US regulators, a milestone for the DNA-modifying technology Crispr. Crispr Co-Inventor, 2020 Nobel Prize winner in chemistry, and Innovative Genomics Institute founder Jennifer Doudna joins Caroline Hyde and Ed Ludlow on “Bloomberg Technology.” ——– Like this video? Subscribe to Bloomberg Technology on YouTube: Watch the…

Published

on

A gene-editing therapy for sickle cell disease was approved by US regulators, a milestone for the DNA-modifying technology Crispr. Crispr Co-Inventor, 2020 Nobel Prize winner in chemistry, and Innovative Genomics Institute founder Jennifer Doudna joins Caroline Hyde and Ed Ludlow on “Bloomberg Technology.”
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
Twitter:
Facebook:
Instagram:

Continue Reading
Advertisement
27 Comments

27 Comments

  1. @duran9664

    December 8, 2023 at 3:33 pm

    The beginning of the walking dead 😵 💀 ☠️

    • @sinside318

      December 8, 2023 at 3:49 pm

      Nope, just science helping people live normal lives…

    • @ashchbkv6965

      December 8, 2023 at 7:31 pm

      when your knowledge of reality comes from tv shows and movies 💀the last of us and world war z are way better btw

  2. @duran9664

    December 8, 2023 at 3:50 pm

    Great job 👏
    Swifties r in dire need for gene editing treatment🥹

  3. @mtas5560

    December 8, 2023 at 4:21 pm

    Totally rad

  4. @ground752

    December 8, 2023 at 4:46 pm

  5. @MM-sq5pf

    December 8, 2023 at 5:18 pm

    NOOOOOOOOOOOOOOOOO NOOOOOOOOOOOOOOOOO!!!!!!

    • @TommyOrigami

      December 8, 2023 at 5:52 pm

      The white liberal part of me thinks this is disgusting.

      But the rest of me is laughing my ass off! 🤣🤣🤣

  6. @TommyOrigami

    December 8, 2023 at 6:08 pm

    China already has a massive database database of human DNA. How far away is an ACTUAL race war?

    ‘course China would be killing off almost all their best customers with ‘Agent Roundeye’

    But there are many roads to world domination. Xi couldn’t do it with money.

    But Xi can isolate the country to ensure privacy while his world-trained scientists have another go at it with genetics.

    I sure hope the AI & chip embargoes hold.

  7. @remildejesus

    December 8, 2023 at 6:15 pm

    just wow!

  8. @clr18287

    December 8, 2023 at 6:32 pm

    Civilization, if it survives, will look back in 50 years and view this as the end of humanity. Where does it end? It’s only a matter of time that CRISPR is put into a weaponized mosquito virus… If you understand biology, you understand the reality of this.

  9. @Jay-nice

    December 8, 2023 at 8:54 pm

    @6:13

  10. @user-hv8rh6de5u

    December 8, 2023 at 10:30 pm

    👍👍I was at a retirement seminar and the speaker spoke on how he quit his job after he made well over $950,000 PROFIT within 3months he invested $120,000. I just need creative ideas to afford my retirement!

  11. @user-qx1wl2um2k

    December 9, 2023 at 2:00 am

    2.2 million dollars for the treatment.

    • @U23721

      December 9, 2023 at 2:15 am

      A lifetime of treatment for sickle cell anemia is estimated at 1.4 – 1.8 million. I bet costs will half every few years for this treatment just like all other new technologies as they scale. In 5 years, bet it will be significantly cheaper than a lifetime of treatment and thus insurance will actually save money to cover the treatment.

    • @bme7491

      December 9, 2023 at 1:53 pm

      Not to mention all the pain of the chemotherapy as a prerequisite and the months of being in a hospital bed.

    • @indiancitizen3013

      December 10, 2023 at 12:16 am

      ​@@U23721
      Absolutely it would be cheaper within few years

    • @AnirbanGhosh-eu5fm

      December 10, 2023 at 2:16 am

      Actually lifetime cost is between $4-6MM (as per CEO of Vertex) and that’s not even counting the humanistic cost of carrying this deadly disease.

    • @indiancitizen3013

      December 10, 2023 at 2:46 am

      @@AnirbanGhosh-eu5fm
      Less than 1% patient can afford it
      If every pharmaceutical company give this treatment then it would be cheaper soon

  12. @dscuffman7679

    December 9, 2023 at 2:37 am

    This is the woman who should be mentioned during woman’s history month. Not Beyonce, not Michelle Obama, and not Hillary Clinton. This woman and madam curry

  13. @nohemyrueda4254

    December 9, 2023 at 8:34 am

    Gracias a Dios 🙏🏾encontraron este tratamiento por miles de personas q cargan ese gen en su ADN.

  14. @christiangaviriaalvarez693

    December 9, 2023 at 11:45 am

    Charging 2.2 million dollars to cure a disease that will save lives is a travesty. These pharma companies don’t care about saving lives, they care about filling their pockets from the sick. In my opinion, after the banks, they are public enemy number 2.

  15. @indiancitizen3013

    December 10, 2023 at 12:19 am

    When it’ll come to other countries?

    • @AnirbanGhosh-eu5fm

      December 10, 2023 at 2:15 am

      Approved in UK, USA and Bahrain. Pending approval in Saudi Arabia. Vertex has global presence so I am sure this is going to be rolled out in all regions in the next 2 years.

  16. @Lovelife-lw7fy

    December 10, 2023 at 3:13 am

    There is NO WAY anyone can afford 2.2 million dollars and No way their insurance would cover the costs . Pharma should be ashamed

  17. @jimbojimbo6873

    December 10, 2023 at 6:53 am

    Hopefully not too far away from genetic modification

  18. @andreialcaza

    December 10, 2023 at 2:08 pm

    Lets gooo !

Leave a Reply

Your email address will not be published. Required fields are marked *

Bloomberg Technology

Applied Materials’ Results, OpenAI-Reddit Partnership | Bloomberg Technology

Bloomberg’s Caroline Hyde and Ed Ludlow break down Applied Materials’ earnings, which failed to impress investors. Plus, OpenAI and Reddit announce a partnership to bring its content to ChatGPT and other products, and CoreWeave secures nearly $8 billion in private debt. ——– “Bloomberg Technology” is our daily news program focused exclusively on technology, innovation and…

Published

on

Bloomberg’s Caroline Hyde and Ed Ludlow break down Applied Materials’ earnings, which failed to impress investors. Plus, OpenAI and Reddit announce a partnership to bring its content to ChatGPT and other products, and CoreWeave secures nearly $8 billion in private debt.
——–
“Bloomberg Technology” is our daily news program focused exclusively on technology, innovation and the future of business hosted by Ed Ludlow from San Francisco and Caroline Hyde in New York.

Like this video? Subscribe and turn on the notifications for Bloomberg Technology on YouTube:

Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

Get the latest in tech from Silicon Valley and around the world here:

Follow Ed Ludlow on Twitter here:
Follow Caroline Hyde on Twitter here:

Connect with us on…
Twitter:
Facebook:
Instagram:

Continue Reading

Bloomberg Technology

Reddit Forges Pact With OpenAI on Content for ChatGPT

Reddit forged a partnership with OpenAI that will bring its content to the chatbot ChatGPT and other products, while also helping the social media company add new artificial intelligence features to its forums. Bloomberg’s Shirin Ghaffary joins Ed Ludlow and Caroline Hyde on “Bloomberg Technology.” ——– Like this video? Subscribe to Bloomberg Technology on YouTube:…

Published

on

Reddit forged a partnership with OpenAI that will bring its content to the chatbot ChatGPT and other products, while also helping the social media company add new artificial intelligence features to its forums. Bloomberg’s Shirin Ghaffary joins Ed Ludlow and Caroline Hyde on “Bloomberg Technology.”
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

 
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
 
Listen to the daily Bloomberg Technology podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Applied Materials Forecast Fails to Impress After Rally

Applied Materials, the largest US maker of chipmaking machinery, failed to impress investors with its latest forecast following a rally in the shares this year. Advisors Capital Management Partner & Portfolio Manager JoAnne Feeney joins Ed Ludlow and Caroline Hyde to discuss the results and the future of the broader chip industry on “Bloomberg Technology.”…

Published

on

Applied Materials, the largest US maker of chipmaking machinery, failed to impress investors with its latest forecast following a rally in the shares this year. Advisors Capital Management Partner & Portfolio Manager JoAnne Feeney joins Ed Ludlow and Caroline Hyde to discuss the results and the future of the broader chip industry on “Bloomberg Technology.”
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

 
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
 
Listen to the daily Bloomberg Technology podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Trending